EyePoint Pharmaceuticals, Inc.

NasdaqGM:EYPT Stock Report

Market Cap: US$498.1m

EyePoint Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:EYPT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Aug 24BuyUS$39,750Goran AndoIndividual5,000US$7.95
20 Aug 24BuyUS$19,997Wendy DiCiccoIndividual2,567US$7.79
19 Aug 24BuyUS$99,750Karen ZaderejIndividual12,500US$7.98
16 Aug 24BuyUS$25,003Nancy LurkerIndividual3,173US$7.88
12 Jul 24SellUS$18,619David GuyerIndividual1,850US$10.06
03 Jun 24SellUS$19,050David GuyerIndividual1,850US$10.30
14 May 24SellUS$23,401David GuyerIndividual1,850US$12.65
06 May 24BuyUS$10,081,721Cormorant Asset Management, LPCompany850,000US$12.36
18 Apr 24BuyUS$10,489,446Cormorant Asset Management, LPCompany581,765US$18.90
24 Jan 24SellUS$874,200Nancy LurkerIndividual35,000US$24.98
11 Jan 24BuyUS$17,051,100Cormorant Asset Management, LPCompany855,000US$21.32
11 Jan 24SellUS$37,159,225Ocumension TherapeuticsCompany1,910,500US$19.45

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EYPT?
Owner TypeNumber of SharesOwnership Percentage
Public Companies100,2210.143%
Individual Insiders470,1400.67%
VC/PE Firms3,572,3355.09%
General Public6,177,5028.8%
Hedge Funds17,292,24324.6%
Institutions42,547,68060.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49%.

Top Shareholders

Top 25 shareholders own 79.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.9%
Cormorant Asset Management, LP
8,325,000US$59.1m0%3.27%
7.38%
Suvretta Capital Management, LLC
5,175,823US$36.7m0%1.39%
5.92%
BlackRock, Inc.
4,155,158US$29.5m10.4%no data
5.68%
Franklin Resources, Inc.
3,983,714US$28.3m9.19%0.01%
5.4%
Adage Capital Management, L.P.
3,791,420US$26.9m5.57%0.05%
5.36%
T. Rowe Price Group, Inc.
3,760,967US$26.7m-17.8%no data
5.28%
Federated Hermes, Inc.
3,707,364US$26.3m92.7%0.07%
5.09%
TCG Crossover Management, LLC
3,572,335US$25.4m287%2.33%
4.34%
The Vanguard Group, Inc.
3,048,182US$21.6m9.87%no data
2.52%
Morgan Stanley, Investment Banking and Brokerage Investments
1,765,565US$12.5m-19.5%no data
2.21%
Essex Woodlands Management, Inc.
1,551,521US$11.0m0%2.63%
2.01%
Citadel Advisors LLC
1,407,353US$10.0m3.9%0.01%
1.94%
Patient Square Capital, LP
1,361,979US$9.7m0%3.67%
1.73%
State Street Global Advisors, Inc.
1,215,881US$8.6m-0.32%no data
1.71%
Geode Capital Management, LLC
1,199,056US$8.5m16.1%no data
1.68%
Goldman Sachs Group, Investment Banking and Securities Investments
1,175,404US$8.3m54.5%no data
1.56%
Octagon Capital Advisors LP
1,093,503US$7.8m0%1.28%
1.5%
5AM Venture Management, LLC
1,050,000US$7.5m2,000%1.69%
1.48%
Perceptive Advisors LLC
1,037,274US$7.4m62%0.17%
1.01%
Finepoint Capital LP
707,404US$5.0m0%0.58%
0.92%
Deutsche Asset & Wealth Management
647,848US$4.6m2.26%no data
0.72%
Bank of America Corporation, Asset Management Arm
502,654US$3.6m166%no data
0.69%
Point72 Asset Management, L.P.
483,289US$3.4m-56.5%0.01%
0.67%
Northern Trust Global Investments
471,783US$3.3m47.4%no data
0.67%
UBS Asset Management AG
469,789US$3.3m74.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EyePoint Pharmaceuticals, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Andrew D'SilvaB. Riley Securities, Inc.
Jennifer KimCantor Fitzgerald & Co.